Navigation Links
Experimental treatments restore partial vision to blind people
Date:10/20/2009

Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored vision in an animal model and identified ways to improve stem cell treatments.

The new studies tested both people and animals with two degenerative eye diseases: retinitis pigmentosa and age-related macular degeneration. These diseases destroy the light-sensitive nerve cells in the retina, leading to blindness. In all, vision loss and eye disease affect 3.6 million Americans and cost the United States $68 billion each year.

Research released today shows that:

  • A retinal prosthesis restores partial vision to people who are totally blind. The prosthesis, made of an array of electrodes, transmits visual information captured by a video camera (Jessy Dorn, PhD, abstract 216.6, see attached summary).

  • Transplanted "sheets" of fetal retinal cells improve visual acuity in several people with retinitis pigmentosa and age-related macular degeneration (Robert B. Aramant, PhD, abstract 837.12, see attached summary).

  • Engineered, light-sensitive proteins restore vision in a mouse study of retinitis pigmentosa. The findings could lead to new treatments for people with degenerative retinal diseases (Natalia Caporale, PhD, abstract 806.10, see attached summary).

  • As researchers strive to develop stem cell therapies for eye disease, a new method increases the yield of retinal cells from human stem cells derived from both embryonic and adult tissue (Jason S. Meyer, PhD, abstract 113.1, see attached summary).

"Basic neuroscience research has formed the basis for significant progress in treating eye disease," said press conference moderator Rachel O. L. Wong, PhD, of the University of Washington, an expert on visual system development. "These studies would not be possible without technological advances and basic science research that continues to explain the normal function and development of the visual system," Wong said.


'/>"/>

Contact: Kat Snodgrass
ksnodgrass@sfn.org
202-299-7957
Society for Neuroscience
Source:Eurekalert

Related biology news :

1. Experimental Biology 2008 meets in San Diego April 5-9
2. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
3. Experimental Biology and Medicine announces expansion into Asia, opens new office
4. Experimental chemotherapy regimen shows promise in treating advanced lung cancer
5. French scientist wins the Journal of Experimental Biology Outstanding Paper Prize
6. Survival in a Changing World: The Journal of Experimental Biology 2009 symposium
7. 40 minority scientists receive travel fellowships to Experimental Biology 2009 in New Orleans
8. Experimental treatment halts hypoxic-ischemic brain injury in newborns
9. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
10. Paradigm shift in Alzheimerss research: new treatments
11. NIH selects LIAI for major study on allergy molecular causes and possible treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology: